High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
复制标题
淋巴瘤患者的大剂量治疗和自体外周血干细胞移植。
DOI：
10.1182/blood.v74.4.1260.bloodjournal7441260
复制
发表时间：
1989
期刊：
影响因子：
20.3
通讯作者：
D. Weisenburger
中科院分区：
文献类型：
--
作者：
A. Kessinger;J. O. Armitage;Smith Dm;J. Landmark;P. Bierman;D. Weisenburger
难治性霍奇金病40例（24例患者）或非霍奇金淋巴瘤（16例患者）考虑接受高剂量治疗，但由于BM转移、既往盆腔放疗而不接受自体骨髓移植（ABMT），在接受高剂量治疗和自体外周血（PB）的常规收获部位有肿瘤或细胞减少骨髓累及骨髓的病史造血干细胞移植在可评价的患者中，随着循环中性粒细胞消失、红细胞和血小板输注依赖性的发展，在移植后中位数25天，循环粒细胞和足够的血小板重新出现，以满足血小板输注的需要。23例患者达到临床完全缓解（CR）。所有40例患者的预计2年无事件生存率为24%，非霍奇金淋巴瘤患者为49%。预计霍奇金病患者的18个月无事件生存率为15%。PB干细胞移植为难治性淋巴瘤患者提供了一个给予高剂量挽救治疗的机会，否则这些患者不适合这种治疗。对于其中一些患者，高剂量治疗延长了生存期，没有肿瘤进展。
Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation. Disappearance of circulating neutrophils and development of RBC and platelet transfusion-dependence was followed, in the evaluable patients, by reappearance of 0.5 x 10(9)/L circulating granulocytes and sufficient platelets to obviate the need for platelet transfusions at a median of 25 days after transplantation. Twenty-three patients experienced a clinical complete remission (CR). The projected 2-year event-free survival was 24% for all 40 patients and 49% for the non-Hodgkin's lymphoma patients. The projected 18-month event-free survival for the Hodgkin's disease patients was 15%. PB stem cell transplantation provided an opportunity to administer high-dose salvage therapy to patients with refractory lymphoma who otherwise were not candidates for such therapy. For some of those patients, the high-dose therapy produced prolonged survival, free of tumor progression.